Charles River Laboratories Intl. Inc vs Plug Power Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.12 (market cap $14.23B), while Plug Power Inc trades at $1.73 (market cap $2.42B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.9× Plug Power Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Plug Power Inc for 41 Days on average.
| CRL | PLUG | |
|---|---|---|
Market Cap | $14.23B | $2.42B |
Volume | 1,176,885 | 53,851,702 |
Sector | Health | Industrials |
52-Week High | $310.77 | $4.14 |
52-Week Low | $149.93 | $1.73 |
Typical Hold Time | 33 Days | 41 Days |
Enterprise Value | $17.06B | $3.29B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Plug Power (PLUG) trades at $1.715, down 3.65% on the day, reflecting ongoing operational challenges despite recent positive developments. The stock shows bearish technical signals with negative moving averages, though oscillators suggest potential oversold conditions. Fundamentally, the company continues to report significant losses with a net income margin of -220.59% and negative cash flow from operations of $535.84 million in 2025. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, providing some optimism for future growth in the green hydrogen sector.
The outlook remains challenging with persistent financial losses and high cash burn, though analyst consensus suggests potential upside with a $3.13 price target. Key risks include execution challenges in scaling hydrogen infrastructure, competitive pressures, and dependence on external financing. Investment opportunity exists for those betting on long-term hydrogen adoption, but requires high risk tolerance given current financial instability and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →